InvestSMART

Imricor Medical Systems Inc (ASX: IMR) - Announcements

Current share price for IMR : $1.330 0.03 (2.31%)+

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$477 Application for quotation of securities - IMR 27 Oct 2025 9:18AM $1.440 $1.330 fallen by 7.64%
$477 Imricor Q3 CY25 Quarterly Activities Report and Appendix 4C 22 Oct 2025 9:42AM $1.475 $1.330 fallen by 9.83%
$477 Canaccord Drug & Device Conference Noosa 2025 Presentation 21 Oct 2025 8:46AM $1.465 $1.330 fallen by 9.22%
$477 Imricor Performs World's First PFA Ablation in the iCMR 20 Oct 2025 8:57AM $1.500 $1.330 fallen by 11.33%
$477 Notification of cessation of securities - IMR 13 Oct 2025 9:48AM $1.500 $1.330 fallen by 11.33%
$477 Notification regarding unquoted securities - IMR 10 Oct 2025 10:35AM $1.545 $1.330 fallen by 13.92%
$477 Imricor Completes Human Factors Study for FDA 18 Sep 2025 8:53AM $1.405 $1.330 fallen by 5.34%
$477 Application for quotation of securities - IMR 15 Sep 2025 11:13AM $1.415 $1.330 fallen by 6.01%
$477 Application for quotation of securities - IMR 8 Sep 2025 1:07PM $1.365 $1.330 fallen by 2.56%
$477 Submission of FDA 510(k) Approval for Vision-MR Diagnostic 1 Sep 2025 9:19AM $1.405 $1.330 fallen by 5.34%
$477 Submission of FDA 510(k) Approval for Vision-MR Diagnostic 1 Sep 2025 9:19AM $1.405 $1.330 fallen by 5.34%
$477 Release from Voluntary Escrow 28 Aug 2025 10:27AM $1.400 $1.330 fallen by 5%
$477 H1 FY25 Results Investor Presentation 26 Aug 2025 8:06AM $1.345 $1.330 fallen by 1.12%
$477 Imricor releases Half Year Results for 1H 2025 26 Aug 2025 8:06AM $1.345 $1.330 fallen by 1.12%
$477 Imricor releases Half Year Results for 1H 2025 26 Aug 2025 8:06AM $1.345 $1.330 fallen by 1.12%
$477 Appendix 4D and Half Year Report & Accounts 26 Aug 2025 8:05AM $1.345 $1.330 fallen by 1.12%
$477 Appendix 4D and Half Year Report & Accounts 26 Aug 2025 8:05AM $1.345 $1.330 fallen by 1.12%
$477 FY25 1H Results Webinar Notification 15 Aug 2025 11:32AM $1.395 $1.330 fallen by 4.66%
$477 Canaccord 45th Annual Growth Conference Presentation 13 Aug 2025 8:33AM $1.355 $1.330 fallen by 1.85%
$477 Imricor Q2 CY25 Quarterly Activities Report and Appendix 4C 28 Jul 2025 8:23AM $1.260 $1.330 risen by 5.56%
$477 Regulatory and Business Update 10 Jul 2025 9:10AM $1.555 $1.330 fallen by 14.47%
$477 Notification regarding unquoted securities - IMR 3 Jul 2025 10:51AM $1.530 $1.330 fallen by 13.07%
$477 Imricor Receives CE Mark Approval for NorthStar 10 Jun 2025 8:37AM $1.660 $1.330 fallen by 19.88%
$477 Appendix 3Y - MT 6 Jun 2025 8:23AM $1.700 $1.330 fallen by 21.76%
$477 Appendix 3Y - SW 6 Jun 2025 8:22AM $1.700 $1.330 fallen by 21.76%

76 - 100 of 605 results

Page 4 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.